MedTrace Logo

Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

NCT05231369 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-02-10

No results posted yet for this study

Summary

This is a phase 1 study that will evaluate the safety and immunogenicity of ChulaCov19 BNA159 mRNA vaccine in healthy adults.

Conditions

  • Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Immune Response of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
  • Assess Which Dose is Appropriate to Use

Interventions

BIOLOGICAL

ChulaCov19 BNA159 mRNA vaccine

ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine

Sponsors & Collaborators

  • Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University

    collaborator UNKNOWN

  • Academic Clinical Research Office (ACRO), Faculty of Medicine, Khon Kaen University

    collaborator UNKNOWN

  • BioNet-Asia

    collaborator UNKNOWN

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Sivaporn Gatechompol, MD · HIV-NAT, Thai Red Cross - AIDS Research Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-14
Primary Completion
2023-07-01
Completion
2023-07-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05231369 on ClinicalTrials.gov